INTRODUCTION

Gastrointestinal symptoms are a near-universal problem among patients treated for cancer. Gastrointestinal toxicity can manifest as diarrhea, nausea, vomiting, bloating, pain, weight loss and/or dehydration. In addition to reducing quality of life, gastrointestinal toxicity and other symptoms in cancer patients can lead to premature discontinuation of therapy and/or dose reductions of chemotherapy and radiation, impacting efficacy of treatment.

In preclinical studies the amino acid mixture has shown to promote tightening of the mucosal barrier, proliferation of crypt cells, increase villous height and absorption of fluid, electrolytes and nutrients following radiation.

OBJECTIVE

If these pre-clinical effects translate to humans exposed to radiation or other forms of cancer therapy, they could provide a safe and logical treatment for symptoms of gastrointestinal toxicity and dehydration in oncology patients.

The objective of this pragmatic study, featuring a retrospective analysis of prospectively collected data, was to determine if consumption of the amino acid mixture is associated with a decrease in patient-reported symptoms of gastrointestinal toxicity during radiotherapy and/or chemotherapy.

METHODS

Patients were eligible to receive a 16-day supply of the amino acid formulation if they developed gastrointestinal toxicity during chemotherapy and/or radiotherapy. Patients completed a questionnaire before starting the beverage and again 16 days later.

Tumor and treatment characteristics were reported, as were type and severity of gastrointestinal symptoms, other adverse effects (weight loss, dehydration, malaise) and current weight.

Changes in symptom severity and in a composite score were determined for diarrhea, nausea, dehydration, weight loss, and malaise.

RESULTS

Charts were reviewed for 139 patients who were given AA-ORS

21 patients did not note the duration of AA-ORS use

15 patients had GI side effects but were lost to follow-up

118 patients recorded sufficient data for analysis

43 patients used the AA-ORS for 1-6 days

60 patients used the AA-ORS for at least 7 days

Table 1. Type and severity of initial symptoms

<table>
<thead>
<tr>
<th>AA-ORS consumption group</th>
<th>Total</th>
<th>0 days</th>
<th>1-6 days</th>
<th>≥ 7 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>118</td>
<td>15</td>
<td>43</td>
<td>60</td>
</tr>
<tr>
<td>Males</td>
<td>56</td>
<td>7</td>
<td>24</td>
<td>25</td>
</tr>
<tr>
<td>Females</td>
<td>62</td>
<td>8</td>
<td>19</td>
<td>35</td>
</tr>
<tr>
<td>Age in years (min, max)</td>
<td>71 (24, &gt;89)</td>
<td>68 (24, &gt;89)</td>
<td>70 (42, &gt;89)</td>
<td>72 (41, &gt;89)</td>
</tr>
<tr>
<td>Severity of initially reported symptoms**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>34 (29%)</td>
<td>4 (20%)</td>
<td>13 (27%)</td>
<td>17 (31%)</td>
</tr>
<tr>
<td>Moderate</td>
<td>64 (54%)</td>
<td>15 (75%)</td>
<td>21 (43%)</td>
<td>28 (52%)</td>
</tr>
<tr>
<td>Mild</td>
<td>31 (26%)</td>
<td>7 (35%)</td>
<td>15 (31%)</td>
<td>9 (17%)</td>
</tr>
</tbody>
</table>

A 78% improvement in the composite symptom score was reported in patients who used the formulation for ≥7 days, compared to 46% improvement in those who used it for 1-6 days and 7% improvement in those who did not use it at all. Among the individual symptoms, statistically significant improvements were noted for diarrhea, dehydration and weight maintenance.

Figure 1. Study design and flow chart.

Figure 2. Effects of different durations of the AA-ORS use on gastrointestinal symptoms in cancer patients. The percent of patients reporting improvement in diarrhea (A), nausea (B) dehydration (C) malaise (D) and weight maintenance (E) were obtained from symptom inventories in patient charts. The composite score (F) reflects collective improvement in all five of these symptoms. Sample sizes for diarrhea and the composite score were sufficient for 3-way analyses, which yielded p<0.005 for diarrhea and p<0.0001 for the composite score.

CONCLUSIONS

Use of an amino acid formulation was strongly associated with reduced gastrointestinal toxicity in patients undergoing cancer therapy. Additional clinical studies to evaluate beneficial effects of this medical food are warranted.

REFERENCES